Replies to post #151482 on Biotech Values

[bladerunner1717]

ARRY CC notes

McBio,,

I think you forgot to mention that ARRY has applied for late-breaker status at the ACR next week in order to present the updated 797 trial regarding the identification of a biomarker for "disease-modification" in OA. No guarantee that they will get to present; the conference is just ten days away. The idea for 797 is for a "opiod-replacement therapy." Also, a reference was made to the fact that 797 showed some efficacy in the reiief of pain due to bone mets.

Also, Squarer made reference a couple of times to NVS' R&D day next week. Squarer implied that there should be some info on MEK-162.


Bladerunner

[mcbio]

ARRY - 11/5/12 CC (ASH abstracts)

[I assume, in particular, that ARRY will be discussing the biomarker they have identified for ARRY-520. Not sure if there will be a lot of new meaningful info on ARRY-614.]

http://finance.yahoo.com/news/array-biopharma-hold-conference-call-123000607.html

Array BioPharma to Hold Conference Call on Monday, November 5, 2012 to Discuss Submitted ASH Abstracts

BOULDER, Colo., Nov. 1, 2012 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will hold a conference call on Monday, November 5, 2012 at 4:30 p.m. Eastern Time to discuss submitted 2012 American Society of Hematology Annual Meeting abstracts on ARRY-520, a KSP inhibitor for multiple myeloma and ARRY-614, a dual p38/Tie2 inhibitor for myelodysplastic syndromes. Ron Squarer, Chief Executive Officer and Kevin Koch, Ph.D., President and Chief Scientific Officer, will lead the call.

Conference Call Information

Date:
Monday, November 5, 2012

Time:
4:30 p.m. Eastern Time

Toll-Free:
[phone]

Toll:
[phone]

Pass Code:
33684333

Webcast & Conference Call Slides: http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-irhome

A replay of the call will be available as a webcast on www.arraybiopharma.com

About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small-molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company, with two wholly-owned programs, ARRY-614 and ARRY-520, and three partnered programs, selumetinib (with AstraZeneca), MEK162 (with Novartis), and danoprevir (with InterMune / Roche), having the potential to begin Phase 3 or pivotal trials by the end of calendar year 2013. For more information on Array, please go to www.arraybiopharma.com.